VEGFA and wet macular degeneration: Anti-vascular endothelial growth factor (anti-VEGF) is the most well-known type of single-target therapy in ocular disease and is currently being investigated for wet AMD, diabetic macular edema, diabetic retinopathy, and macular edema due to retinal vein occlusion [10].